Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
18.10
+0.13 (0.70%)
Jul 7, 2026, 9:33 AM EDT - Market open
Amylyx Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
136
Market Cap
2.01B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 87.37M | -293.42M | -77.06% |
| Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
| Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
| Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
| Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
| Dec 31, 2019 | 1.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.53B |
| Perrigo Company | 4.18B |
| Phibro Animal Health | 1.50B |
| Trulieve Cannabis | 1.17B |
| Prestige Consumer Healthcare | 1.09B |
| ANI Pharmaceuticals | 923.71M |
| BioCryst Pharmaceuticals | 885.72M |
| Supernus Pharmaceuticals | 776.83M |
AMLX News
- 3 days ago - Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 12 days ago - Amylyx price target raised to $40, named a Best Idea at Guggenheim - TheFly
- 14 days ago - Amylyx to present data from first-in-human, dose-ranging Phase 1 Lumina trial - TheFly
- 14 days ago - Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 - Business Wire
- 26 days ago - Amylyx Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026 - Business Wire
- 4 weeks ago - Amylyx Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 7 weeks ago - Amylyx announces publication of Phase 2 open-label HELIOS trial data - TheFly